The latest meta-analysis conducted by Yu et al. (2019), which included 83 studies with a total of 21,612 samples, identified a significant association between SFRP2 promoter hypermethylation (in different biological tissues) and an increased risk of CRC, with an overall pooled odds ratio (OR) of 8.41 (95% CI 5.91–11.97) [8]. This evidence concerns the gene SFRP2 and colorectal carcinoma.